Baird lowered the firm’s price target on Iqvia (IQV) to $223 from $256 and keeps a Neutral rating on the shares. The firm said they are concerned about CRO marketplace dynamics near term and with 60% of the company reporting slow or weakening trend, they question whether the 40% that is improving will do much more than provide balance.